Results: 5

1.
Figure 3

Figure 3. From: Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium.

Representative photographs of a patient with significant improvement in conjunctival hyperemia after repeated subconjunctival ranibizumab injections, and photographs of a patient with only mild improvement in conjunctival hyperemia. Representative photographs of a patient with significant improvement in conjunctival hyperemia after repeated subconjunctival ranibizumab injections. (A) Preinjection photograph; (B) postinjection photograph. Representative photographs of a patient with only mild improvement in conjunctival hyperemia after repeated subconjunctival ranibizumab injections. (C) Preinjection photograph; (D) postinjections photograph.

Volkan Hurmeric, et al. Clin Ophthalmol. 2013;7:467-473.
2.
Figure 1

Figure 1. From: Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium.

(A) Slit lamp photograph of a patient before subconjunctival injection. (B) Area of neovascularization (asterisk) was outlined with the software.
Note: The location of the limbus and subconjunctival vessels (grey lines) was marked at the baseline visit.

Volkan Hurmeric, et al. Clin Ophthalmol. 2013;7:467-473.
3.
Figure 4

Figure 4. From: Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium.

Corneal vessel area at each time point in group 1.
Notes: Arrows demonstrate the subconjunctival ranibizumab injection in each patient. Percentages represent changes in the vessel area between 6 months and baseline. Positive values indicate increasing area, while negative numbers indicate decreasing area.
Abbreviation: Preinjec, preinjection.

Volkan Hurmeric, et al. Clin Ophthalmol. 2013;7:467-473.
4.
Figure 2

Figure 2. From: Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium.

Conjunctival hyperemia scores in patients who received a single subconjunctival ranibizumab injection (group 1) and multiple injections (group 2) for a pterygium recurrence (scale 0 to 4).

Volkan Hurmeric, et al. Clin Ophthalmol. 2013;7:467-473.
5.
Figure 5

Figure 5. From: Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium.

Corneal vessel area at each time point in group 2.
Notes: Arrows demonstrate the subconjunctival ranibizumab injections in each patient. Percentages represent changes in the vessel area between 6 months and baseline. Positive values indicate increasing area, while negative numbers indicate decreasing area.
Abbreviation: Preinjec, preinjection.

Volkan Hurmeric, et al. Clin Ophthalmol. 2013;7:467-473.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk